Please enter valid quantity
Please log in to add favorites.
NULL OR EMPTY CART
Well format: 384-well
|Number of Rows||16|
|Number of Columns||24|
|Well volume||28 µL|
|Recommended working volume||10 µL- 20 µL|
|Well diameter (mm)||3.3|
|Well depth (mm)||5.3|
|A1 to top offset (mm)||8.99|
|A1 to side offset (mm)||12.13|
|Well-to-well spacing (mm)||4.5|
|Detection Method||Luminescence, Alpha|
|Product Brand Name||AlphaPlate|
|Unit Size||Case of 50|
|Wells Number||384 well plate|
The main vectors of gene therapy in research are viruses. The most popular tool for gene delivery is a genetically modified lentivirus. Modified lentivirus (HIV-1) vectors retain their ability to infect undivided cells, thereby increasing their ability to transduce a wide variety of cells, including those that are difficult to transduce. This advantage enables the stable long-term expression of a transgene.
In immunotherapy, CAR-T cells are manufactured by transducing the CAR gene with an HIV-1 vector in T cells to express a specific chimeric p24 protein on their surface. This allows them to recognize cancer cells and destroy them. These CAR-T cells must be generated individually to treat each patient.
This application note demonstrates a comparative quantification of the p24 titer in a lentiviral GFP control sample using Alliance HIV-1 p24 Antigen ELISA and p24 AlphaLISA immunoassay platforms.
Check out the different sections of this application note:
While fundamental knowledge about tumor immunology has exploded recently, a new therapeutic approach to cancer is taking off: immunotherapy. Instead of directly attacking tumor cells, the idea is to help the immune system recognize and destroy them.
The use of CAR-T cells (Chimeric Antigen Receptor-T Cells), a new avenue of immunotherapy, consists in genetically modifying the patient's immune cells to arm them against a tumor. Concretely, T lymphocytes are taken from the patient's blood and modified in vitro. This leads to their expression of specific surface receptors, which recognize a tumor antigen. Once modified, these CAR-T cells are multiplied and re-injected into the patient's body in large quantities. There they go on to destroy cancer cells after binding to the tumor antigen, releasing a mixture of cytokines and pro-inflammatory chemokines.
This application note focuses on detecting cytokine and chemokine secretion using two orthogonal no-wash immunoassays, AlphaLISA® and HTRF®, in an in vitro co-culture model with CAR-T cells and CD19 positive Raji cells targeting tumors.
A variety of chemotherapeutic drugs with different modes of action have been developed and tested as potential therapies for colorectal cancer. Characterizing the effects of potential drugs with different modes of action is a key part of the process.
In this application note you will learn:
Technical advancements in antibody engineering has brought about greater interest in more novel antibody therapeutic design and the emergence of new classes of antibody therapeutics called bispecific antibodies (bsAbs). The principle behind bispecific antibody design is to create an antibody / antibody fragment to two or more binding sites to help with the treatment of complex diseases.
As more bsAbs are produced as therapeutics, fast and accurate methods for functionally evaluating and characterizing the stability of these antibodies are necessary during both discovery and development stages, as well as during formulation and quality analysis.
In this application note, we demonstrate how AlphaLISA® assay technology with the EnVision® multimode plate reader can be used for bispecific antibody detection, through an example application to characterize the binding and specificity of a mouse bispecific antibody targeting mouse TIGIT and mouse PD-L1.
You will find out:
When PD-1, which is expressed on the T cell, binds to PD-L1 expressed on the tumor cell, the T cell response is suppressed. Utilization of this pathway leads to tumor immune escape and promotes tumor cell growth. In fact, PD-L1 expression increases with tumor severity in many types of cancer. Release of a soluble form of PD-L1 (sPD-L1) into circulation is one mechanism that tumors may use to evade the immune response; however, it is unclear whether sPD-L1 can bind PD-1 and deliver an inhibitory signal. Previous studies have shown that soluble forms of PD-L1 have been detected in supernatants of cancer cell lines.
Traditional methods for assessing soluble and membrane-associated PD-L1 are wash-based ELISA assays, which typically require 5-6 hours of assay time. AlphaLISA® technology provides a rapid, no-wash bead-based alternative to traditional ELISAs. In this Application Note, we demonstrate how AlphaLISA is used to detect the presence of PD-L1.
Tumor Necrosis Factors (TNFs) are cytokines that are the primary modifiers of inflammatory and immune response. Researchers have shown that a soluble form of TNFR1 (sTNFR1) is a truncated version of the receptor produced by the disintegration and extracellular release of membranous protein on the cell surface (ectodomain shedding). sTNFR1 is found in healthy and diseased patients alike, however increased sTNFR1 levels are an indicator for disease states such as inflammation, infection, and asthma.
Here we present a way to measure TNFR1 using homogeneous bead-based AlphaLISA assay. The human TNFR1 AlphaLISA® detection kit was designed for the quantitative determination of soluble TNFR1 in serum and cell culture media. This technical note further demonstrates the functionality of the kit by detecting sTNFR1 in cell supernatant as well as TNFR1 on the cell membrane.